PATEL SUJAL M (CEO, President, and Secretary) purchased 2.0% of their position (200K shares) of NAUTILUS BIOTECHNOLOGY, INC. on the open market
Open‑market purchase worth $135.6K — a small addition. The strongest form of insider conviction signal.
P · 2 purchases
Filed: 9/9/2025ACC: 0001378830-25-000003
DirectorOfficer10% Owner· CEO, President, and Secretary
Since Jun 2021
+200K
Net shares
Net buyer
$135.6K
Total acquired
2
Open market trades
2B · 0S
2
Total transactions
200K acquired
Non-Derivative Transactions2
Common Stock
Direct
Shares
+116.50K
Price / share
$0.67
Trade value
$78.54K
% of position
1.1%
9/5/2025
10.14M→10.26M
Common Stock
Direct
Shares
+83.50K
Price / share
$0.68
Trade value
$57.03K
% of position
0.8%
9/8/2025
10.26M→10.34M
Total
Net shares
+200K
Net value
$135.57K
| Security | Date | Type | Shares | Price / Share | Trade Value | % of Position | Held Before | Held After |
|---|---|---|---|---|---|---|---|---|
| Common Stock Direct | 9/5/2025 | P · Purchase | +116.50K | $0.67 | $78.54K | 1.1% | 10.14M | 10.26M |
| Common Stock Direct | 9/8/2025 | P · Purchase | +83.50K | $0.68 | $57.03K | 0.8% | 10.26M | 10.34M |
| Total | +200K | $135.57K | ||||||
Derivative Transactions0
No derivative transactions reported
Non-Derivative Holdings (Post-Transaction)2
Common Stock
IndirectShares owned5.28M
Common Stock
IndirectShares owned1.81M
Total
7.09M indirect7.09M
| Security Title | Shares Owned | Ownership Type |
|---|---|---|
| Common Stock | 5.28M | Indirect |
| Common Stock | 1.81M | Indirect |
| Total | 7.09M | 7.09M indirect |
Derivative Holdings (Post-Transaction)0
No derivative holdings reported